These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16263095)

  • 21. Normal hypocretin-1 (orexin A) levels in cerebrospinal fluid in patients with idiopathic intracranial hypertension.
    Poca MA; Galard R; Serrano E; Merino MA; Pozo-Rosich P; Solana E; Mestres O; de la Calzada MD; Sahuquillo J
    Acta Neurochir Suppl; 2012; 114():221-5. PubMed ID: 22327697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease.
    Asai H; Hirano M; Furiya Y; Udaka F; Morikawa M; Kanbayashi T; Shimizu T; Ueno S
    Clin Neurol Neurosurg; 2009 May; 111(4):341-4. PubMed ID: 19097685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease.
    Constantinescu R; Romer M; Oakes D; Rosengren L; Kieburtz K
    Parkinsonism Relat Disord; 2009 Mar; 15(3):245-8. PubMed ID: 19056308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypersomnia and low cerebrospinal fluid hypocretin levels in acute disseminated encephalomyelitis.
    Yoshikawa S; Suzuki S; Kanbayashi T; Nishino S; Tamai H
    Pediatr Neurol; 2004 Nov; 31(5):367-70. PubMed ID: 15519122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid homovanillic acid and parkinsonism in Huntington's disease.
    Kurlan R; Goldblatt D; Zaczek R; Jeffries K; Irvine C; Coyle J; Shoulson I
    Ann Neurol; 1988 Aug; 24(2):282-4. PubMed ID: 2972251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cocaine- and amphetamine-regulated transcript is increased in Huntington disease.
    Björkqvist M; Leavitt BR; Nielsen JE; Landwehrmeyer B; Ecker D; Mulder H; Brundin P; Petersén A
    Mov Disord; 2007 Oct; 22(13):1952-4. PubMed ID: 17722045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Normal levels of cerebrospinal fluid hypocretin-1 and daytime sleepiness during attacks of relapsing-remitting multiple sclerosis and monosymptomatic optic neuritis.
    Knudsen S; Jennum PJ; Korsholm K; Sheikh SP; Gammeltoft S; Frederiksen JL
    Mult Scler; 2008 Jul; 14(6):734-8. PubMed ID: 18505777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Normal hypocretin-1 levels in the cerebrospinal fluid of patients with fatal familial insomnia.
    Martínez-Rodríguez JE; Sanchez-Valle R; Saiz A; Lin L; Iranzo A; Mignot E; Santamaria J
    Sleep; 2003 Dec; 26(8):1068. PubMed ID: 14746394
    [No Abstract]   [Full Text] [Related]  

  • 30. The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene test.
    Schneider SA; Walker RH; Bhatia KP
    Nat Clin Pract Neurol; 2007 Sep; 3(9):517-25. PubMed ID: 17805246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder.
    Brundin L; Björkqvist M; Petersén A; Träskman-Bendz L
    Eur Neuropsychopharmacol; 2007 Sep; 17(9):573-9. PubMed ID: 17346943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypocretin/orexin disturbances in neurological disorders.
    Fronczek R; Baumann CR; Lammers GJ; Bassetti CL; Overeem S
    Sleep Med Rev; 2009 Feb; 13(1):9-22. PubMed ID: 18819824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid orexin in aneurysmal subarachnoid haemorrhage - a pilot study.
    Ang BT; Tan WL; Lim J; Ng I
    J Clin Neurosci; 2005 Sep; 12(7):758-62. PubMed ID: 16150596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Narcolepsy and the hypocretins.
    Wurtman RJ
    Metabolism; 2006 Oct; 55(10 Suppl 2):S36-9. PubMed ID: 16979425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid.
    Sarchielli P; Rainero I; Coppola F; Rossi C; Mancini M; Pinessi L; Calabresi P
    Cephalalgia; 2008 Jul; 28(7):714-22. PubMed ID: 18479471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy.
    Schuld A; Blum WF; Pollmächer T
    Ann Neurol; 2002 May; 51(5):660; author reply 660-1. PubMed ID: 12112120
    [No Abstract]   [Full Text] [Related]  

  • 37. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
    Glynn D; Reim K; Brose N; Morton AJ
    Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circadian variation of hypocretin-1 (orexin A) in restless legs syndrome.
    Baier PC; Göder R; Hallschmid M
    Sleep Med; 2009 Feb; 10(2):271; author reply 272. PubMed ID: 19013101
    [No Abstract]   [Full Text] [Related]  

  • 39. Orexin and psychiatric symptoms in suicide attempters.
    Brundin L; Petersén A; Björkqvist M; Träskman-Bendz L
    J Affect Disord; 2007 Jun; 100(1-3):259-63. PubMed ID: 17141878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid eye movement sleep disturbances in Huntington disease.
    Arnulf I; Nielsen J; Lohmann E; Schiefer J; Wild E; Jennum P; Konofal E; Walker M; Oudiette D; Tabrizi S; Durr A
    Arch Neurol; 2008 Apr; 65(4):482-8. PubMed ID: 18413470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.